Articles Tagged With:
-
Self-Managed Abortion: A Guide to Harm Reduction and Patient-Centered Care
Even before the Dobbs v Jackson Women’s Health Organization decision, access to safe, legal abortion within the formal healthcare system was increasingly restricted. In this context, patients may turn to self-managed abortion (SMA). Clinicians should understand the course of SMA, including its overall safety, rare complications, and potential legal risks to patients.
-
Treatment of Acute Vertigo
Treating acute vertigo with an antihistamine was more effective than benzodiazepines for acute symptoms. However, there was no difference between the two medications in terms of resolution within one week or one month.
-
An Unhealthy Gut Microbiome May Cause Colorectal Cancer
An E. coli variant found in the Western diet was associated with a higher incidence of colorectal cancer.
-
Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure
An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.
-
Appropriate Management of Thoracic Aortic Aneurysms
Among patients with arch and descending thoracic aorta aneurysms followed over a mean of 20 months, aneurysm-related mortality was predicted by the size and growth rate of the aneurysms, along with age and sex.
-
Remaining Questions in Syphilis Treatment
Eight leading experts on sexually transmitted diseases convened to discuss key questions in the management of syphilis in adults with and without HIV infection based on a systematic review of the literature. More than 3,000 articles were screened, and the discussion focused on 95 relevant publications and three main topics.
-
Betibeglogene Autotemcel Suspension (Zynteglo)
The FDA has approved the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions.
-
Hot Trials from the European Society of Cardiology Annual Congress
Below are some highlights from four key studies presented in Barcelona, Spain, between Aug. 26 and Aug. 29, 2022, along with Dr. Crawford’s personal commentary on each.
-
REVIVED Shows No PCI Benefit for Patients with Coronary Disease, Reduced EF
Researchers randomly assigned patients with an ejection fraction ≤ 35% and severe coronary disease to percutaneous coronary intervention or optimal medical therapy alone. After 3.4 years median follow-up, researchers noted no significant differences between groups in terms of all-cause death or heart failure hospitalization.
-
Statins Plus Ezetimibe vs. Statins Alone
A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.